9 JULY - FDA has approved the first device that uses a genetically engineered human protein for use in the lower region of the spine to treat degenerative disc disease, a major cause of back pain for many adults.
DEVICE USES ENGINEERED PROTEIN TO TREAT BACKDISORDER -- FDA has approved the first device that uses agenetically engineered human protein for use in the lower regionof the spine to treat degenerative disc disease, a major cause ofback pain for many adults.http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01155.html
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.